Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...

T cell lymphomas are among the toughest blood cancers to treat. Immunotherapy, despite its success in many cancers, struggles ...

Debi Weiss went to the doctor's office with what she thought were worsening flu symptoms, but got a very different diagnosis ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in ...

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

She thought it was a case of the flu. As the weeks passed, the Pilates instructor's symptoms worsened. Weiss could no longer ...

Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...